NO312708B1 - Radioaktive liposomer til terapi - Google Patents

Radioaktive liposomer til terapi Download PDF

Info

Publication number
NO312708B1
NO312708B1 NO20000855A NO20000855A NO312708B1 NO 312708 B1 NO312708 B1 NO 312708B1 NO 20000855 A NO20000855 A NO 20000855A NO 20000855 A NO20000855 A NO 20000855A NO 312708 B1 NO312708 B1 NO 312708B1
Authority
NO
Norway
Prior art keywords
liposomes
stated
composition
radionuclide
solution
Prior art date
Application number
NO20000855A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000855D0 (no
NO20000855L (no
Inventor
Roy H Larsen
Gjermund Henriksen
Original Assignee
Anticancer Therapeutic Inv Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inv Sa filed Critical Anticancer Therapeutic Inv Sa
Priority to NO20000855A priority Critical patent/NO312708B1/no
Publication of NO20000855D0 publication Critical patent/NO20000855D0/no
Priority to CNB018053726A priority patent/CN100350981C/zh
Priority to EA200200793A priority patent/EA005624B1/ru
Priority to NZ520848A priority patent/NZ520848A/en
Priority to JP2001559512A priority patent/JP4933712B2/ja
Priority to MXPA02008110A priority patent/MXPA02008110A/es
Priority to EP01910251A priority patent/EP1257299B9/en
Priority to DE60112251T priority patent/DE60112251T2/de
Priority to CZ20023164A priority patent/CZ299032B6/cs
Priority to PL358541A priority patent/PL201398B1/pl
Priority to AT01910251T priority patent/ATE300316T1/de
Priority to DK01910251T priority patent/DK1257299T3/da
Priority to ES01910251T priority patent/ES2247069T3/es
Priority to AU3782701A priority patent/AU3782701A/xx
Priority to AU2001237827A priority patent/AU2001237827B2/en
Priority to US09/790,260 priority patent/US6592843B2/en
Priority to BR0108572-7A priority patent/BR0108572A/pt
Priority to KR1020027010848A priority patent/KR100822566B1/ko
Priority to PCT/NO2001/000065 priority patent/WO2001060417A2/en
Priority to UA2002086850A priority patent/UA73160C2/uk
Priority to CA002400994A priority patent/CA2400994C/en
Publication of NO20000855L publication Critical patent/NO20000855L/no
Publication of NO312708B1 publication Critical patent/NO312708B1/no
Priority to ZA200206500A priority patent/ZA200206500B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20000855A 2000-02-21 2000-02-21 Radioaktive liposomer til terapi NO312708B1 (no)

Priority Applications (22)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi
CA002400994A CA2400994C (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
AT01910251T ATE300316T1 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
ES01910251T ES2247069T3 (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
NZ520848A NZ520848A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
JP2001559512A JP4933712B2 (ja) 2000-02-21 2001-02-21 放射線治療用リポソーム
MXPA02008110A MXPA02008110A (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
EP01910251A EP1257299B9 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
DE60112251T DE60112251T2 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
CZ20023164A CZ299032B6 (cs) 2000-02-21 2001-02-21 Konjugátorový systém
PL358541A PL201398B1 (pl) 2000-02-21 2001-02-21 System koniugatora radionuklid-liposom, sposób jego wytwarzania, zastosowanie systemu koniugatora do wytwarzania roztworu farmaceutycznego, zastosowanie terapeutyczne systemu koniugatora oraz zestaw do wytwarzania systemu koniugatora
CNB018053726A CN100350981C (zh) 2000-02-21 2001-02-21 有放射活性的治疗性脂质体
DK01910251T DK1257299T3 (da) 2000-02-21 2001-02-21 Radioaktive, terapeutiske liposomer
EA200200793A EA005624B1 (ru) 2000-02-21 2001-02-21 Радиоактивные терапевтические липосомы
AU3782701A AU3782701A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
AU2001237827A AU2001237827B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
US09/790,260 US6592843B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
BR0108572-7A BR0108572A (pt) 2000-02-21 2001-02-21 Sistema conjugador, método para preparar um sistema conjugador radiorrotulado, uso do sistema conjugador, método para utilizar o sistema conjugador, e, kit para a preparação do sistema conjugador
KR1020027010848A KR100822566B1 (ko) 2000-02-21 2001-02-21 방사성 치료 리포좀
PCT/NO2001/000065 WO2001060417A2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
UA2002086850A UA73160C2 (uk) 2000-02-21 2001-02-21 Кон'югаційна система, що являє собою радіоактивні терапевтичні ліпосоми, спосіб їх одержання та застосування
ZA200206500A ZA200206500B (en) 2000-02-21 2002-08-14 Radioactive therapeutic liposomes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Publications (3)

Publication Number Publication Date
NO20000855D0 NO20000855D0 (no) 2000-02-21
NO20000855L NO20000855L (no) 2001-08-22
NO312708B1 true NO312708B1 (no) 2002-06-24

Family

ID=19910768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Country Status (21)

Country Link
US (1) US6592843B2 (pl)
EP (1) EP1257299B9 (pl)
JP (1) JP4933712B2 (pl)
KR (1) KR100822566B1 (pl)
CN (1) CN100350981C (pl)
AT (1) ATE300316T1 (pl)
AU (2) AU2001237827B2 (pl)
BR (1) BR0108572A (pl)
CA (1) CA2400994C (pl)
CZ (1) CZ299032B6 (pl)
DE (1) DE60112251T2 (pl)
DK (1) DK1257299T3 (pl)
EA (1) EA005624B1 (pl)
ES (1) ES2247069T3 (pl)
MX (1) MXPA02008110A (pl)
NO (1) NO312708B1 (pl)
NZ (1) NZ520848A (pl)
PL (1) PL201398B1 (pl)
UA (1) UA73160C2 (pl)
WO (1) WO2001060417A2 (pl)
ZA (1) ZA200206500B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
EP1289570B1 (en) * 2000-06-16 2008-09-10 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of alpha-emitters and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
NZ595758A (en) * 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
PL1735013T3 (pl) * 2004-02-20 2012-07-31 Algeta Asa Cząstki hydroksyapatytu alfa- i beta-emitujące
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US20070224115A1 (en) * 2006-03-22 2007-09-27 The Regents Of The University Of California Polymeric chelators for radionuclide delivery systems
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US20100178244A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2011006510A1 (en) 2009-07-17 2011-01-20 Technical University Of Denmark Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
JP2011111438A (ja) * 2009-11-30 2011-06-09 Akita Univ 有機金属錯体を有効成分として含有する抗がん剤
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
JP5947807B2 (ja) * 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ ナノ粒子組成物への放射性核種の封入
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
DE102011079031A1 (de) * 2011-07-12 2013-01-17 Algeta Asa Flüssigkeitsbehälter
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
EP2968150B1 (en) * 2013-03-11 2020-08-19 Wayne State University Liposomes comprising europium cryptands and their use
SG11201706849SA (en) * 2015-02-26 2017-09-28 Sciencons AS Radiopharmaceutical solutions with advantageous properties
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
NO3061464T3 (pl) * 2015-02-26 2018-03-24
PT3111959T (pt) * 2015-07-03 2017-12-14 Oncoinvent As Partículas e suspensões radioterapêuticas
SG10202009424TA (en) 2016-03-24 2020-11-27 Bayer Pharma AG Radio-pharmaceutical complexes
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
IL263808B2 (en) * 2016-06-24 2025-04-01 Sciencons AS Preparation of 212PB-labeled monoclonal antibodies
CN120643844A (zh) 2017-05-11 2025-09-16 阿尔法陶医疗有限公司 用于近距离放射治疗装置的聚合物涂层
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
WO2021013978A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
JP7544819B2 (ja) 2019-12-05 2024-09-03 サイエンコンス アクスイェ セルスカプ 高度に精製された２１２Ｐｂの製造
AU2021400142B2 (en) 2020-12-16 2024-11-21 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
DK482685D0 (da) * 1984-10-22 1985-10-21 Hope Nat Medical Center Fremgangsmaade til tilfoersel af micellulaere partikler, der indkapslerbilleddannende og kemoterapeutiske midler, til tumorer i et legeme
CA1314209C (en) * 1987-11-04 1993-03-09 Gary Fujii Composition and method for use for liposome encapsulated compounds for neutron capture tumor therapy
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
EP0646019B9 (en) * 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法

Also Published As

Publication number Publication date
CZ299032B6 (cs) 2008-04-09
MXPA02008110A (es) 2003-12-11
AU2001237827B2 (en) 2007-11-22
KR100822566B1 (ko) 2008-04-16
AU3782701A (en) 2001-08-27
US6592843B2 (en) 2003-07-15
EP1257299A2 (en) 2002-11-20
EP1257299B1 (en) 2005-07-27
ATE300316T1 (de) 2005-08-15
AU2001237827B8 (en) 2001-08-27
EA005624B1 (ru) 2005-04-28
ES2247069T3 (es) 2006-03-01
EA200200793A1 (ru) 2003-02-27
NZ520848A (en) 2005-02-25
PL358541A1 (pl) 2004-08-09
WO2001060417A2 (en) 2001-08-23
PL201398B1 (pl) 2009-04-30
CA2400994C (en) 2009-07-07
KR20020092963A (ko) 2002-12-12
WO2001060417A3 (en) 2002-02-07
CZ20023164A3 (cs) 2003-04-16
JP4933712B2 (ja) 2012-05-16
DE60112251T2 (de) 2006-03-30
US20010048914A1 (en) 2001-12-06
CA2400994A1 (en) 2001-08-23
UA73160C2 (uk) 2005-06-15
EP1257299B9 (en) 2005-11-30
JP2003522808A (ja) 2003-07-29
CN1404402A (zh) 2003-03-19
DE60112251D1 (de) 2005-09-01
ZA200206500B (en) 2003-08-14
NO20000855D0 (no) 2000-02-21
NO20000855L (no) 2001-08-22
DK1257299T3 (da) 2005-11-21
CN100350981C (zh) 2007-11-28
BR0108572A (pt) 2002-11-19

Similar Documents

Publication Publication Date Title
NO312708B1 (no) Radioaktive liposomer til terapi
Henriksen et al. Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides
Westrøm et al. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution
ES2991349T3 (es) Preparación de anticuerpos monoclonales marcados con 212Pb
Becker et al. Cyclotron production of 43Sc and 44gSc from enriched 42CaO, 43CaO, and 44CaO targets
Lin et al. Fully automated preparation of 68Ga-PSMA-11 at curie level quantity using cyclotron-produced 68Ga for clinical applications
Thakral et al. In-house preparation and quality control of Ac-225 prostate-specific membrane antigen-617 for the targeted alpha therapy of castration-resistant prostate carcinoma
JP2026050460A (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
EP3452436B1 (en) In-kit preparation of gallium-68 labelled radiopharmaceuticals
TW202200214A (zh) 放射性標記psma結合配位體的方法及其套組
Rabie et al. Preparation, quality control and biodistribution study of 68Ga-BPAMD: Optimized production with an in-house 68Ge-68Ga generator
Ermolaev et al. 225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates
CN119630434A (zh) 用于靶向分子成像的铜的放射性药物组合物
Daha et al. Production of^ sup 177^ Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical
Kim et al. Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu] ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F] DCFPyL and [68Ga] PSMA-11
Sahiralamkhan et al. Irradiation parameters play a crucial role in the (n, γ) production of 170Tm suitable for clinical use in bone pain palliation
Shetty et al. Preparation and evaluation of [64Cu] Cu-labeled bisphosphonate amide of DOTA using reactor-produced 64Cu as an affordable skeletal PET imaging agent
Ayranov et al. Quality control and clinical application of two bone imaging 99m Tc radiopharmaceuticals
Van Dong et al. Study on preparation of 17'7Lu, labeling with DOTATATE for using in diagnosis and treatment neuroendocrine tumors
Nair et al. 90Y/177Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation
JOUHARI et al. PRODUCTION OF177LU AND FORMULATION OF ETHYLENE DIAMINE TETRAMETHYLENE PHOSPHONATE (EDTMP) KITS AS A BONE-SEEKING RADIOPHARMACEUTICAL

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees